Table 2.
Unadjusted outcome rates and adjusted risk differences utilizing 3 gestational age strata
| Outcome (by gestational age subgroup) | SGA n/N (%) |
Non-SGA n/N (%) |
p-value | Adjusted RD (95% CI) |
|---|---|---|---|---|
| Individual Outcomes | ||||
| Death | ||||
| 23 0/7 – 25 6/7 weeks | 53/140 (37.9) | 191/980 (19.5) | <0.001 | 0.23 (0.14, 0.31) |
| 26 0/7 – 28 6/7 weeks | 44/241 (18.3) | 95/1724 (5.5) | <0.001 | 0.14 (0.08, 0.19) |
| 29 0/7 – 31 6/7 weeks | 15/362 (4.1) | 46/3261 (1.4) | <0.001 | 0.03 (0.01, 0.05) |
| Grade 3–4 IVH among survivors | ||||
| 23 0/7 – 25 6/7 weeks | 13/87 (14.9) | 123/789 (15.6) | 0.87 | 0.009 (−0.07, 0.09) |
| 26 0/7 – 28 6/7 weeks | 10/197 (5.1) | 90/1629 (5.5) | 0.79 | 0.002 (−0.03, 0.03) |
| 29 0/7 – 31 6/7 weeks | 2/347 (0.6) | 38/3215 (1.2) | 0.31 | −0.006 (−0.02, 0.004) |
| BPD among survivors | ||||
| 23 0/7 – 25 6/7 weeks | 72/87 (82.8) | 544/789 (69.0) | 0.007 | 0.14 (0.05, 0.23) |
| 26 0/7 – 28 6/7 weeks | 125/197 (63.5) | 583/1629 (35.8) | <0.001 | 0.27 (0.19, 0.35) |
| 29 0/7 – 31 6/7 weeks | 91/347 (26.2) | 367/3215 (11.4) | <0.001 | 0.14 (0.09, 0.18) |
| Stage 3–5 ROP among survivors | ||||
| 23 0/7 – 25 6/7 weeks | 24/87 (27.6) | 130/789 (16.5) | 0.01 | 0.13 (0.03, 0.23) |
| 26 0/7 – 28 6/7 weeks | 16/197 (8.1) | 57/1629 (3.5) | 0.002 | 0.05 (0.002, 0.10) |
| 29 0/7 – 31 6/7 weeks | 4/347 (1.2) | 23/3215 (0.7) | 0.37 | 0.005 (−0.007, 0.02) |
| Composite Outcomes | ||||
| Death or grade 3–4 IVH | ||||
| 23 0/7 – 25 6/7 weeks | 66/140 (47.1) | 314/980 (32.0) | <0.001 | 0.20 (0.11, 0.28) |
| 26 0/7 – 28 6/7 weeks | 54/241 (22.4) | 185/1724 (10.7) | <0.001 | 0.13 (0.07, 0.19) |
| 29 0/7 – 31 6/7 weeks | 17/362 (4.7) | 84/3261 (2.6) | 0.02 | 0.02 (0.001, 0.05) |
| Death or BPD | ||||
| 23 0/7 – 25 6/7 weeks | 125/140 (89.3) | 735/980 (75.0) | <0.001 | 0.14 (0.08, 0.21) |
| 26 0/7 – 28 6/7 weeks | 169/241 (70.1) | 678/1724 (39.3) | <0.001 | 0.30 (0.23, 0.37) |
| 29 0/7 – 31 6/7 weeks | 106/362 (29.3) | 413/3261 (12.7) | <0.001 | 0.16 (0.141 0.21) |
| Death or stage 3–5 ROP | ||||
| 23 0/7 – 25 6/7 weeks | 77/140 (55.0) | 321/980 (32.8) | <0.001 | 0.26 (0.16, 0.36) |
| 26 0/7 – 28 6/7 weeks | 60/241 (24.9) | 152/1724 (8.8) | <0.001 | 0.17 (0.11, 0.23) |
| 29 0/7 – 31 6/7 weeks | 19/362 (5.3) | 69/3261 (2.1) | <0.001 | 0.03 (0.01, 0.06) |
| Death or major morbidity | ||||
| 23 0/7 – 25 6/7 weeks | 127/140 (90.7) | 786/980 (80.2) | 0.003 | 0.11 (0.05, 0.17) |
| 26 0/7 – 28 6/7 weeks | 173/241 (71.8) | 743/1724 (43.1) | <0.001 | 0.29 (0.22, 0.35) |
| 29 0/7 – 31 6/7 weeks | 109/362 (30.1) | 462/3261 (14.2) | <0.001 | 0.16 (0.11, 0.20) |
BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; RD, risk difference; ROP, retinopathy of prematurity; SGA, small for gestational age